In-hospital Mortality Among Patients with Intracranial Tumors at a Tertiary Hospital in Luanda, Angola: A Retrospective Cohort Study

Imagine the human brain as a bustling, high-tech city. Inside this city, traffic flows smoothly, lights stay green, and the power grid hums perfectly. But sometimes, a construction crew starts building something in the wrong place, or a foreign object crashes into the streets. In medical terms, these are "intracranial tumors"—growths inside the skull that can crowd out healthy brain tissue. When this happens, the city's emergency services (the doctors) have to rush in. Sometimes, the situation is so critical that the patient doesn't make it out of the hospital alive. This is called "in-hospital mortality."

Why does anyone care about this? Because knowing who is most at risk helps hospitals prepare their emergency rooms and decide how to treat patients. It's like a fire department trying to figure out which neighborhoods are most likely to have fires so they can station trucks there. For a long time, we've had great maps for cities in wealthy countries, but for many places in Africa, the maps were blank. We didn't know how often these "brain city" emergencies ended in tragedy, or what factors made them worse. This study steps into that blank space to draw the first map for Angola.

---

The Story of the Brain City in Luanda

In the bustling capital of Angola, Luanda, a team of doctors at Hospital do Prenda decided to look back at their own records to solve a mystery. They wanted to know: among patients admitted with brain tumors between 2020 and 2025, who didn't make it out of the hospital, and why? They gathered data on 93 different hospital visits (admissions) involving these tumors. Think of each admission as a single "mission" for the hospital team.

Out of these 93 missions, 21 ended in tragedy. That's about 23 out of every 100 patients, or roughly one in four. That's a heavy number, suggesting that for many, the journey through the hospital was a race against time that they couldn't win.

The Clues: Age, Surgery, and the Type of Monster

The researchers played detective, looking at several clues to see what linked the patients who died to the ones who survived.

First, they looked at age. It turned out that older patients were in much more danger. In the initial look at the data, patients aged 50 and older were about 5.7 times more likely to die in the hospital than younger patients. It's like driving a car: if you're driving a brand-new sports car (a young, resilient body), you might handle a sudden storm better than an older, more fragile vehicle. The data showed that the patients who died were significantly older on average than those who survived.

Next, they checked if surgery saved the day. Did the patients who got an operation survive more often? Surprisingly, the answer was "not really." The data showed no clear link between having surgery and living or dying. But here's the twist: the doctors didn't flip a coin to decide who got surgery. They chose to operate on patients who looked strong enough to survive the cut, and they avoided operating on those who were too sick or whose tumors were in impossible spots. This is called "confounding by indication." It's like seeing that people who call a tow truck are more likely to have broken cars, and concluding that the tow truck caused the break. The surgery wasn't the problem; the severity of the illness was the reason surgery was (or wasn't) chosen. So, the paper warns us: don't blame the surgery, and don't assume surgery is a magic cure just because it didn't show up as a "savior" in this specific list.

Finally, they looked at the type of tumor. This was the most revealing clue. They grouped the tumors into "high-risk" monsters (like glioblastoma, which is a very aggressive, fast-growing tumor, or metastatic disease, where cancer spreads from elsewhere in the body) and "other" types (like meningiomas, which can be slower-growing).

The Big Reveal

When the researchers ran a special, careful math test (called Firth penalized logistic regression) to account for the fact that they only had 21 deaths to study, the picture sharpened.

While age was a strong warning sign at first glance, it turned out that the type of tumor was the real boss of the situation. Even after adjusting for age and surgery, patients with the "high-risk" tumors (glioblastoma or metastatic disease) were nearly 6 times more likely to die in the hospital than those with other types of tumors.

The paper suggests that the reason older age seemed so dangerous at first was partly because older patients were more likely to have these nasty, aggressive tumors. Once you separate the "bad tumor" factor from the "old age" factor, the tumor itself is the strongest predictor of a short-term tragedy.

What This Means

This study doesn't claim to have solved the mystery of brain tumors forever. It's a first look, a "hypothesis-generating" peek into a world where data is scarce. It tells us that in Luanda, the type of tumor biology—how aggressive the growth is—matters more for immediate survival than just the patient's age or whether they got surgery.

The authors are careful to say they can't prove that surgery doesn't help, because the data is too messy to prove cause-and-effect perfectly. But they do confirm that for these specific patients, the nature of the disease was the heaviest weight on the scale.

In the end, this paper is a call to action. It shows that even in resource-limited settings, hospitals can keep track of their patients and learn from them. By understanding that aggressive tumors are the biggest short-term threat, doctors can better prepare their teams, manage expectations, and perhaps one day, find ways to tip the scales in favor of the patients. It's a small step, but in the world of brain cancer, every step counts.